标题
The MAPK pathway across different malignancies: A new perspective
作者
关键词
-
出版物
CANCER
Volume 120, Issue 22, Pages 3446-3456
出版商
Wiley
发表日期
2014-06-20
DOI
10.1002/cncr.28864
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Molecular and Histopathologic Characteristics of Multifocal Papillary Thyroid Carcinoma
- (2013) Mona Bansal et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Clinical implications of using molecular diagnostics for ovarian cancers
- (2013) E. C. Kohn et al. ANNALS OF ONCOLOGY
- PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
- (2013) J.-m. Lee et al. ANNALS OF ONCOLOGY
- EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition
- (2013) T. Nakagawa et al. CANCER RESEARCH
- C-RAF Mutations Confer Resistance to RAF Inhibitors
- (2013) R. Antony et al. CANCER RESEARCH
- Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression
- (2013) E. Romano et al. CLINICAL CANCER RESEARCH
- Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
- (2013) A. Spreafico et al. CLINICAL CANCER RESEARCH
- Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer
- (2013) S. Cardarella et al. CLINICAL CANCER RESEARCH
- Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors
- (2013) Karen E. Sheppard et al. EUROPEAN JOURNAL OF CANCER
- Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation
- (2013) X. Deschenes-Simard et al. GENES & DEVELOPMENT
- Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer
- (2013) Mingzhao Xing et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Genetics and biomarkers in personalisation of lung cancer treatment
- (2013) Rafael Rosell et al. LANCET
- Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK
- (2013) H. Vin et al. MOLECULAR CANCER THERAPEUTICS
- Tumour heterogeneity in the clinic
- (2013) Philippe L. Bedard et al. NATURE
- Tumour heterogeneity and cancer cell plasticity
- (2013) Corbin E. Meacham et al. NATURE
- Emerging landscape of oncogenic signatures across human cancers
- (2013) Giovanni Ciriello et al. NATURE GENETICS
- Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer
- (2013) Alan L. Ho et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma
- (2013) June Y. Hou et al. PLoS One
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- A Genome-Scale RNA Interference Screen Implicates NF1 Loss in Resistance to RAF Inhibition
- (2013) Steven R. Whittaker et al. Cancer Discovery
- BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer
- (2012) Rachel N. Grisham et al. CANCER
- Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway
- (2012) Fabien Zassadowski et al. CELLULAR SIGNALLING
- Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
- (2012) M. Mao et al. CLINICAL CANCER RESEARCH
- Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
- (2012) Giacomo Cossa et al. CURRENT PHARMACEUTICAL DESIGN
- The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
- (2012) Antonella De Luca et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- MAP kinase signalling cascades and transcriptional regulation
- (2012) Shen-Hsi Yang et al. GENE
- The transcriptional landscape and mutational profile of lung adenocarcinoma
- (2012) J.-S. Seo et al. GENOME RESEARCH
- BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
- (2012) Maria Colombino et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
- (2012) John Farley et al. LANCET ONCOLOGY
- Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
- (2012) Pasi A Jänne et al. LANCET ONCOLOGY
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
- (2012) King Pan Ng et al. NATURE MEDICINE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- (2012) Jeffrey A. Sosman et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Elucidating Distinct Roles for NF1 in Melanomagenesis
- (2012) Ophélia Maertens et al. Cancer Discovery
- HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation
- (2012) Ken Takezawa et al. Cancer Discovery
- Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
- (2011) Inna V. Fedorenko et al. BIOCHEMICAL PHARMACOLOGY
- Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation
- (2011) L. Xi et al. BLOOD
- Identification of the MEK1(F129L) Activating Mutation as a Potential Mechanism of Acquired Resistance to MEK Inhibition in Human Cancers Carrying the B-RafV600E Mutation
- (2011) H. Wang et al. CANCER RESEARCH
- PTEN Loss Confers BRAF Inhibitor Resistance to Melanoma Cells through the Suppression of BIM Expression
- (2011) K. H. T. Paraiso et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas
- (2011) Avaniyapuram Kannan Murugan et al. CELL CYCLE
- Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
- (2011) Tanios Bekaii-Saab et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
- (2011) Sergey I Nikolaev et al. NATURE GENETICS
- BRAFMutations in Hairy-Cell Leukemia
- (2011) Enrico Tiacci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
- (2011) Mohammad Atefi et al. PLoS One
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
- (2011) L. V. Sequist et al. Science Translational Medicine
- RAF protein-serine/threonine kinases: Structure and regulation
- (2010) Robert Roskoski BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
- (2010) Alexa B. Turke et al. CANCER CELL
- Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function
- (2010) A. Boni et al. CANCER RESEARCH
- Expression and functional role of negative signalling regulators in tumour development and progression
- (2010) Tania Murphy et al. INTERNATIONAL JOURNAL OF CANCER
- SPRED 1 Mutations in a Neurofibromatosis Clinic
- (2010) Talia M. Muram-Zborovski et al. JOURNAL OF CHILD NEUROLOGY
- Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
- (2010) Daniela Matei et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- International network of cancer genome projects
- (2010) Thomas J. Hudson (Chairperson) et al. NATURE
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- Functional Identification of Tumor-Suppressor Genes through an In Vivo RNA Interference Screen in a Mouse Lymphoma Model
- (2009) Anka Bric et al. CANCER CELL
- A New Fork for Clinical Application: Targeting Forkhead Transcription Factors in Cancer
- (2009) J.-Y. Yang et al. CLINICAL CANCER RESEARCH
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAFMutation in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- Oncogene Addiction
- (2008) I. B. Weinstein et al. CANCER RESEARCH
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More